DE3781904T2 - Verfahren zur anwendung von diltiazem, verapamil oder nifedipin mit aktivitaet zur behandlung von schlaganfaellen. - Google Patents

Verfahren zur anwendung von diltiazem, verapamil oder nifedipin mit aktivitaet zur behandlung von schlaganfaellen.

Info

Publication number
DE3781904T2
DE3781904T2 DE8787100195T DE3781904T DE3781904T2 DE 3781904 T2 DE3781904 T2 DE 3781904T2 DE 8787100195 T DE8787100195 T DE 8787100195T DE 3781904 T DE3781904 T DE 3781904T DE 3781904 T2 DE3781904 T2 DE 3781904T2
Authority
DE
Germany
Prior art keywords
verapamil
nifedipine
diltiazem
cerebral
stroke
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE8787100195T
Other languages
German (de)
English (en)
Other versions
DE3781904D1 (de
Inventor
Frank W Marcoux
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Publication of DE3781904D1 publication Critical patent/DE3781904D1/de
Application granted granted Critical
Publication of DE3781904T2 publication Critical patent/DE3781904T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
DE8787100195T 1986-01-10 1987-01-09 Verfahren zur anwendung von diltiazem, verapamil oder nifedipin mit aktivitaet zur behandlung von schlaganfaellen. Expired - Fee Related DE3781904T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/818,505 US4654372A (en) 1986-01-10 1986-01-10 Method for using verapamil for treating stroke

Publications (2)

Publication Number Publication Date
DE3781904D1 DE3781904D1 (de) 1992-11-05
DE3781904T2 true DE3781904T2 (de) 1993-02-25

Family

ID=25225695

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8787100195T Expired - Fee Related DE3781904T2 (de) 1986-01-10 1987-01-09 Verfahren zur anwendung von diltiazem, verapamil oder nifedipin mit aktivitaet zur behandlung von schlaganfaellen.

Country Status (8)

Country Link
US (1) US4654372A (OSRAM)
EP (1) EP0229644B1 (OSRAM)
JP (1) JPS62167725A (OSRAM)
AT (1) ATE81006T1 (OSRAM)
CA (1) CA1284950C (OSRAM)
DE (1) DE3781904T2 (OSRAM)
ES (1) ES2046178T3 (OSRAM)
GR (1) GR3005998T3 (OSRAM)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4871731A (en) * 1987-10-07 1989-10-03 Marion Laboratories, Inc. Captopril and diltiazem composition and the like
DE3737741A1 (de) * 1987-11-06 1989-05-18 Goedecke Ag Oral anzuwendende arzneiform zur einmal taeglichen behandlung der hypertonie mit diltiazemhydrochlorid
KR0133553B1 (ko) * 1989-06-16 1998-04-23 모리다 다까가즈 뇌기능 개선제
RU1804845C (ru) * 1991-02-15 1993-03-30 Институт Органического Синтеза Латвийской Ан Ноотропное вещество
US6083532A (en) 1995-03-01 2000-07-04 Duramed Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers and tablet formed therefrom
US5695781A (en) * 1995-03-01 1997-12-09 Hallmark Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers
EP2322174B1 (en) * 1998-07-10 2015-09-23 Novartis Pharma AG Combined use of valsartan and calcium channel blockers for therapeutic purposes
WO2008031831A2 (en) * 2006-09-12 2008-03-20 Neurosearch A/S Pharmaceutical compositions comprising combinations of an ampa/kainate antagonistic compound and an inhibitor of a multidrug resistance protein
US20220125754A1 (en) * 2019-01-29 2022-04-28 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Treating the causative agent in adhesiogenesis
IL297333B2 (en) * 2020-04-17 2025-09-01 Honeybrains Llc Preparations and methods for treating neuropsychiatric disorders
WO2026002967A1 (en) 2024-06-24 2026-01-02 Universität Linz Leoligin and derivatives thereof as calcium channel blockers for the prevention and/or treatment of related diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4568677A (en) * 1983-07-23 1986-02-04 Pfizer Inc. 2-(4-Pyrimidone alkoxyalkyl) dihydropyridine anti-ischaemic and antihypertensive agents
JPS60130517A (ja) * 1983-12-16 1985-07-12 Mitsui Pharmaceut Inc アレルギ−性鼻炎治療剤

Also Published As

Publication number Publication date
EP0229644A2 (en) 1987-07-22
EP0229644B1 (en) 1992-09-30
DE3781904D1 (de) 1992-11-05
ATE81006T1 (de) 1992-10-15
CA1284950C (en) 1991-06-18
GR3005998T3 (OSRAM) 1993-06-07
JPS62167725A (ja) 1987-07-24
ES2046178T3 (es) 1995-04-01
EP0229644A3 (en) 1989-11-23
US4654372A (en) 1987-03-31

Similar Documents

Publication Publication Date Title
DE60024407T2 (de) (2-imidazolin-2-yl-amino)quinoxaline zur behandlung von neuralen verletzungen
DE69534693T2 (de) Sublinguale Zusammensetzung enthaltend Apomorphine zur Diagnose der funktionellen Impotenz
DE69232263T2 (de) Radikalfänger ("spin traps") zur behandlung von mit oxidation von lipiden und proteinen verbundenen erkrankungen
DE60130813T2 (de) Verfahren zum herbeiführen eines eisprungs mittels eines nicht-polypeptid camp-level-modulators
DE3590035T1 (de) Diphenhydramin enthaltende, analgetische und anti-inflammatorische Mittel und Verfahren zu ihrer Verwendung
DE69327328T2 (de) Verwendund von norastemizol zur behandlung der allergischen rhinitis
DE3781904T2 (de) Verfahren zur anwendung von diltiazem, verapamil oder nifedipin mit aktivitaet zur behandlung von schlaganfaellen.
DE69934305T2 (de) Verwendung von dexmedetomidine zur sedierung auf der intensivstation
DE68923151T2 (de) Verwendung von Trifluormethylphenyl-Tetrahydropyridinen zur Herstellung von Arzneimitteln zur Behandlung anxio-depressiver Erkrankungen.
DE69634773T2 (de) Verminderung des infarktausmasses unter verwendung von citicolin
DE3390116C2 (de) Verbesserte, Koffein enthaltende, analgetische und antiinflammatorische Mittel
DE2823174A1 (de) Arzneimittel fuer die prophylaktische behandlung postoperativer tiefer venenthrombose
DE3390114T1 (de) Verbesserte analgetische und antiinflammatorische, Ibuprofen enthaltende Zubereitungen und Verfahren zu ihrer Herstellung
DE69821498T2 (de) Verwendung von amifostin
DE69413090T2 (de) Verwendung von 5-Amino-Phthaloylhydrazid als antihypoxisches und defensives Mittel
DE69819012T2 (de) Pharmazeutische zusammensetzung zur reduzierung der mcp-1 proteinsynthese
DE69232516T2 (de) Behandlung von neurologischen Zuständen durch eine Interleukin-i-inhibierende Verbindung
DE69131398T2 (de) Verwendung von 5-ht4 rezeptorantagonisten zur behandlung von vorhof-fibrillation und zur vorbeugung von schlaganfall
DE60301862T2 (de) Kombinationsbehandlung bei akutem myokardinfarkt
DE68908485T2 (de) Verwendung von 5-HT1A Agonisten zur Herstellung eines Arzneimittels, das gegen ischämische Verletzungen Schützt.
DE60206169T2 (de) Kombination enthaltend einen p-gp hemmer und einen antiepileptischen wirkstoff
US4696924A (en) Method for using diltiazem for treating stroke
DE69625210T2 (de) Nicorandil gegen angstneurosen
DE69910600T2 (de) Verwendung von metformin gegen die gewichtszunahme, die mit valproat und andere psychotropische arzneimittel verbunden ist
DE69919789T2 (de) Loratadin zur Verwendung als Antiarrhythmikum

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee